This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / TG Therapeutics 2025 Earnings and...
Business earnings report

TG Therapeutics 2025 Earnings and BRIUMVI Data

Analysis based on 6 articles · First reported Jan 13, 2026 · Last updated Mar 09, 2026

Sentiment
70
Attention
6
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The strong financial performance and positive 2026 guidance from TG Therapeutics, driven by the success of Ublituximab, are expected to positively impact investor confidence and potentially lead to an increase in TG Therapeutics' stock price. The continued expansion of Ublituximab's market and positive clinical data reinforce its position as a significant treatment for multiple sclerosis, benefiting the biotechnology and pharmaceutical industries.

biotechnology pharmaceuticals
Event Summary

TG Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting total revenue of $616.3 million for the full year, including $594.1 million in U.S. net revenue for Ublituximab. The company provided strong 2026 financial guidance, targeting $875-900 million in total global revenue. Alongside the earnings report, TG Therapeutics presented new data for Ublituximab at the ACTRIMS annual forum, including updates from real-world studies and designs for pediatric trials. The company also published five-year efficacy and safety data from the ULTIMATE I and II studies in JAMA Neurology and a post hoc analysis in Neurology and Therapy, further supporting Ublituximab's effectiveness in treating relapsing multiple sclerosis. Additionally, TG Therapeutics launched the 'Next In MS' platform in collaboration with Christina Applegate to raise awareness for multiple sclerosis and completed a $100 million share repurchase program, authorizing a new one.

Entities Involved
stock
TG Therapeutics
TG Therapeutics announced strong financial results for Q4 and full year 2025, exceeding revenue targets for Ublituximab and providing positive 2026 guidance. The company also shared positive clinical data for Ublituximab and pipeline updates, reinforcing its market position.
Importance 100.0 Sentiment 75.0
oth
Ublituximab
Ublituximab, a key product for TG Therapeutics, demonstrated significant year-over-year growth in U.S. net revenue and expanded global availability. Positive long-term efficacy and safety data were published, and new studies are underway to further enhance its market potential.
Importance 95.0 Sentiment 80.0
per
Michael S. Weiss
Michael S. Weiss, CEO and Chairman of TG Therapeutics, expressed satisfaction with the company's 2025 performance and optimism for 2026, highlighting Ublituximab's success and ongoing clinical advancements.
Importance 60.0 Sentiment 70.0
priv
Neuraxpharm
Neuraxpharm is TG Therapeutics' ex-U.S. licensing partner, contributing to the global commercialization and approval of Ublituximab in several countries outside the United States.
Importance 30.0 Sentiment 60.0
per
Christina Applegate
Christina Applegate collaborated with TG Therapeutics to launch the 'Next In MS' platform, aiming to raise awareness of multiple sclerosis through unfiltered dialogue.
Importance 20.0 Sentiment 50.0
oth
JAMA Neurology
JAMA Neurology published five-year data from the ULTIMATE I and II Open-Label Extension Study, highlighting Ublituximab's durable clinical efficacy and consistent safety.
Importance 10.0 Sentiment 0.0
oth
Neurology and Therapy
Neurology and Therapy published data from a post hoc pooled analysis of the ULTIMATE I and II studies, reinforcing Ublituximab's efficacy in treating highly active relapsing multiple sclerosis.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.